Generic Name and Formulations:
Granisetron 3.1mg/24hrs; transdermal delivery system (patch).
Kyowa Kirin, Inc.
Indications for SANCUSO:
Prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
≥18yrs: apply one patch to clean, dry, intact healthy skin on upper outer arm 24 to 48 hours before chemotherapy; remove at least 24 hours after chemotherapy is completed. May wear patch for up to 7 days. Do not cut patch.
<18yrs: not recommended.
May mask progressive ilieus and/or gastric distention. Avoid direct sun or UV light (cover patch with clothing during use and for 10 days after removing patch). Avoid exposure to external heat sources (eg, heating pads). Pregnancy (Cat.B). Nursing mothers.
5-HT3 receptor antagonist.
Do not take with other granisetron products. Serotonin syndrome possible esp. with concomitant serotonergic drugs.
Constipation; local irritation (remove patch if severe or if generalized skin reaction occurs), headache; serotonin syndrome (discontinue if occurs).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC